By targeting underlying synovitis, the novel intra-articular liraglutide formulation 4P004 aims to bridge the gap between transient symptom relief and disease modification in knee OA.
A phase 2 trial evaluating CS-1103 in participants with methamphetamine use disorder is expected to begin in the first quarter of 2026. The Food and Drug Administration (FDA) has granted Fast Track ...
Enolen's fast track designation by the FDA aims to expedite its development for localized prostate cancer treatment, addressing unmet medical needs. The localized delivery technology targets ...
The FDA has granted Regenerative Medicine Advanced Therapy designation to NouvNeu001, a cell therapy for Parkinson’s disease. NouvNeu001, developed by iRegene, is the first allogeneic cell therapy ...
FDA fast tracked ZW191 for platinum-resistant ovarian cancer, aiming to speed development of a potential new option for patients with limited treatments. The U.S. Food and Drug Administration (FDA) ...
ABBV-CLS-628 is currently being evaluated in a phase 2 trial in an estimated 240 adults with ADPKD class 1C, 1D, or 1E. The Food and Drug Administration (FDA) has granted Fast Track designation to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results